Superworth

Marker Therapeutics EPS MRKR

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$0.46
Latest quarter, Q2 FY26
−$0.09
Fiscal year 2025
−$0.90

Marker Therapeutics' earnings per share was −$0.46 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.09.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.90n/a
FY2024−$1.20n/a
FY2023−$0.94n/a
FY2022−$3.59n/a
FY2021−$5.60n/a
FY2020−$6.10n/a
FY2019−$4.70n/a
FY2018−$44.30n/a
FY2017−$11.50n/a
FY2016−$9.40n/a
FY2015−$180.30n/a
FY2014−$475.20n/a
FY2013−$547.20n/a
FY2011−$600.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.09n/a−$0.46
Q1 FY26−$0.16n/a−$0.66
Q4 FY25−$0.09n/a−$0.90
Q3 FY25−$0.12n/a−$1.23
Q2 FY25−$0.29n/a−$1.37
Q1 FY25−$0.40n/a−$1.33
Q4 FY24−$0.42n/a−$1.20
Q3 FY24−$0.26n/a−$1.10
Q2 FY24−$0.25−186%−$1.18
Q1 FY24−$0.27n/a−$0.64
Q4 FY23−$0.32n/a−$0.94
Q3 FY23−$0.34n/a−$1.08

Against its peers

Companies in Drug Manufacturers - General nearest Marker Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
MRKRMarker Therapeutics−$0.46
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Marker Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.